Prognostic significance of Paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate

American Journal of Surgical Pathology

Volumn 30, Issue 8, 2006, Pages 980-985

  Tamas, Ecaterina F ^a   Epstein, Jonathan I ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Gleason grading; Neuroendocrine; Paneth cell like cells; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CRYOTHERAPY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; NEEDLE BIOPSY; NEUROSECRETORY CELL; PANETH CELL; PELVIS LYMPH NODE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; SEMINAL VESICLE; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PANETH CELLS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 33747591682     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200608000-00008     Document Type: Article

References (25)

1. Abrahamsson A. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39:135-148.
2. Abrahamsson PA, Vashchenko N. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47:147-155.
3. Adlakha H, Bostwick DG. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol. 1994;25:135-139.
4. Bankhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogrnesis, proliferation and androgen receptor status. Ann Oncol. 2001;12(Suppl. 2):S141-S144.
5. Bollito E, Berruti A, Bellina M, et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol. 2001;12(Suppl. 2):S159-S164.
6. Casella R, Bubendorf L, Sauter G, et al. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol. 1998;160:406-410.
7. Cohen RJ, Glezerson G, Haffejee Z, et al. Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Br J Urol. 1990;66:405-410.
8. Di' Saint Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol. 2001;12(Suppl. 2):S135-S140.
9. Di' Sant Agnese PA. Neuroendocrine differentiation in prostatic adenocarcinoma does not represent true paneth cell differentiation. Hum Pathol. 1994;25:115-116.
10. Di' Sant Agnese PA, Cockett AT. Neuroendocrine differentiation in prostate malignancy. Cancer. 1996;78:357-361.
11. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
12. Fetissof F, Dubois MP, Arbeille-Brassart B, et al. Endocrine cells in the prostate gland, urothelium and brenner tumors. Virchows Arch (Cell Pathol). 1983;42:53-64.
13. Grobholz R, Griebe M, Sauer CG, et al. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol. 2005;36:562-570.
14. Hanazawa K, Higashi N, Kawachi Y, et al. Small cell carcinoma of the prostate with hypercalcemia. Int J Urol. 2005;12:108-110.
15. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol. 2001;12(Suppl. 2):S145-S152.
16. Hansson J, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Scand J Urol Nephrol Suppl. 2003;28-36.
17. Helpap B, Kollermann J, Oehler U. Neuroendocrine differentiation in prostatic carcinomas; histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int. 1999;62:133-138.
18. Islam AM, Kato H, Hayama M, et al. Prostatic adenocarcinoma with marked neuroendocrine differentiation. Int J Urol. 2001;8:412-415.
19. Kawai S, Hiroshima K, Tsukamoto Y, et al. Small cell carcinoma of the prostate expressing prostate-specific antigen and showing syndrome of inappropriate secretion of antidiuretic hormone: an autopsy case report. Pathol Int. 2003;53:892-896.
20. Krijnen JLM, Bogdanowicz JFAT, Seldenrijk CA, et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after neuroendocrine therapy. J Urol. 1997;158:171-174.
21. Mackey JR, Heather-Jane AU, Hugh J, et al. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol. 1998;159:1624-1629.
22. Noordzij MA, Van Der Kwast TH, Van Steenbrugge GJ, et al. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer. 1995;62:252-258.
23. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical pathological and immunohistological study of 27 patients. J Urol. 1992;147:804-807.
24. Weaver MG, Abdul-Karim FW, Srigley J, et al. Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol. 1992;16:62-68.
25. Zarcovich A, Masters J, Carpenter L. Primary carcinoid tumor of the prostate. Pathology. 2005;37:184-186.